Journal
MASS SPECTROMETRY REVIEWS
Volume 26, Issue 3, Pages 451-466Publisher
WILEY
DOI: 10.1002/mas.20125
Keywords
lung cancer; tumor biomarkers; proteomics; mass spectrometry
Categories
Funding
- NCI NIH HHS [K08-CA102545-02, R01-CA100750-02] Funding Source: Medline
Ask authors/readers for more resources
Lung cancer is a devastating illness with an overall poor prognosis. To effectively address this disease, early detection and novel therapeutics are required. Early detection of lung cancer is challenging, in part because of the lack of adequate tumor biomarkers. The goal of this review is to summarize the knowledge of current biomarkers in lung cancer, with a focus oil important serum biomarkers. The current knowledge oil the known serum cytokines and tumor biomarkers of lung cancer will be presented. Emerging trends and new findings in the search for novel diagnostic and therapeutic tumor biomarkers using proteomics technologies and platforms are emphasized, including recent advances in mass spectrometry to facilitate tumor biomarker discovery program ill lung cancer It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication, and finally the treatment of lung cancer with potential novel molecularly targeted therapeutics. (c) 2007 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available